Rallybio shares successful early-stage results for rare disease drug; new trial set for late 2026

Rallybio Corporation RLYB on Tuesday shared results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical trial of RLYB116 for complement-mediated diseases, with its initial ...

Mike Elko believes game-changing transfer portal add the perfect missing piece the Aggies' offense needed

The Texas A&M Aggies carried a strong 2025 season into the offseason, where they pulled off a strong transfer portal haul to ...